In Vivo Targeting of CXCR4-New Horizons
Overview
Affiliations
Given its pre-eminent role in the context of tumor cell growth as well as metastasis, the C-X-C motif chemokine receptor 4 (CXCR4) has attracted a lot of interest in the field of nuclear oncology, and clinical evidence on the high potential of CXCR4-targeted theranostics is constantly accumulating. Additionally, since CXCR4 also represents a key player in the orchestration of inflammatory responses to inflammatory stimuli, based on its expression on a variety of pro- and anti-inflammatory immune cells (e.g., macrophages and T-cells), CXCR4-targeted inflammation imaging has recently gained considerable attention. Therefore, after briefly summarizing the current clinical status quo of CXCR4-targeted theranostics in cancer, this review primarily focuses on imaging of a broad spectrum of inflammatory diseases via the quantification of tissue infiltration with CXCR4-expressing immune cells. An up-to-date overview of the ongoing preclinical and clinical efforts to visualize inflammation and its resolution over time is provided, and the predictive value of the CXCR4-associated imaging signal for disease outcome is discussed. Since the sensitivity and specificity of CXCR4-targeted immune cell imaging greatly relies on the availability of suitable, tailored imaging probes, recent developments in the field of CXCR4-targeted imaging agents for various applications are also addressed.
Martin S, Wendlinger L, Zitti B, Hicham M, Postupalenko V, Marx L EJNMMI Res. 2024; 14(1):77.
PMID: 39196448 PMC: 11358572. DOI: 10.1186/s13550-024-01142-1.
Chemokine receptor PET imaging: Bridging molecular insights with clinical applications.
Hunter C, Larimer B Nucl Med Biol. 2024; 134-135:108912.
PMID: 38691942 PMC: 11180593. DOI: 10.1016/j.nucmedbio.2024.108912.
Palanisamy R, Indrajith Kahingalage N, Archibald D, Casari I, Falasca M Int J Mol Sci. 2024; 25(4).
PMID: 38397018 PMC: 10888694. DOI: 10.3390/ijms25042340.
CXCR4-targeted Theranostics in Hematooncology: Opportunities and Challenges.
Werner R, Haug A, Buske C, Heidegger S, Illert A, Bassermann F Nuklearmedizin. 2024; 63(2):57-61.
PMID: 38190998 PMC: 10963126. DOI: 10.1055/a-2194-9965.
Dreher N, Dorrler A, Kraus S, Higuchi T, Serfling S, Samnick S Clin Nucl Med. 2023; 49(2):146-151.
PMID: 38081189 PMC: 11441726. DOI: 10.1097/RLU.0000000000004974.